{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009247","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.062636+00:00","generated_at":"2026-05-22T03:39:32.265447+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow Q1 revenue $47.8M (+38% YoY); VEVYE revenue $21.5M (+35% QoQ); reaffirms >$280M FY2025 guidance","bullets":["Revenues $47.8M, up 38% YoY; GAAP net loss $(17.8)M; adjusted EBITDA $(2.0)M.","VEVYE revenue $21.5M (+35% QoQ); VAFA launch drove new RXs >4X and prescribers >4X at PhilRx.","VEVYE new patent exp. 2042 added to Orange Book; second production site expected H1 2026.","TRIESENCE received CMS pass-through status Apr 1; accounts ordering more than doubled since Jan.","Refinancing $222.75M debt in active discussions; expect resolution by late summer/early fall."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009247","json":"https://secwatch.observer/filing/0001641172-25-009247.json","markdown":"https://secwatch.observer/filing/0001641172-25-009247.md","text":"https://secwatch.observer/filing/0001641172-25-009247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/0001641172-25-009247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:39:32.265447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}